Article Text

Download PDFPDF
Industry influence in evidence production
  1. Adam G Dunn1,
  2. Florence T Bourgeois2,3,
  3. Enrico Coiera1
  1. 1Centre for Health Informatics, University of New South Wales, Sydney, New South Wales, Australia
  2. 2Children's Hospital Informatics Program, Harvard–MIT Division of Health Sciences and Technology, Children's Hospital Boston, Boston, Massachusetts, USA
  3. 3Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Adam Dunn, Centre for Health Informatics, University of New South Wales, Sydney, NSW 2052 Australia; a.dunn{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In light of a number of recent drug development and marketing controversies, there is increasing public focus on the role of industry in determining how drugs are used.1–3 New methods that evaluate how funding has influenced the design, reporting, and synthesis of evidence from clinical trials have identified the breadth of industry involvement in evidence production. The downstream effects on public health remain difficult to quantify. In order to identify and mitigate the potential effects of any one type of trial sponsor, we argue that these new methods should now be used routinely and systematically, in a process we call evidence surveillance.

Impact of industry on medical practice

There is compelling evidence that the pharmaceutical industry can influence clinical practice. A handful of notable cases illustrate some of the tactics employed by industry to ensure market uptake and widespread use of its products. The rofecoxib (Vioxx) case demonstrates how diluting the evidence base with positive reports may have led to the prolonged use of the drug and may have caused tens of thousands of additional heart attacks and strokes in the USA alone.2 Other examples of translation problems occurred with rosiglitazone (Avandia), where industry affiliation was associated with more favourable conclusions about cardiovascular risk,4 and oseltamivir (Tamiflu), where unpublished and previously inaccessible trial results may hold information about serious adverse effects related to its use.3

These examples suggest that our system of evidence production and translation remains susceptible to the agendas of drug-makers, which may not …

View Full Text


  • Contributors All authors contributed to the conception and writing of the manuscript.

  • Funding We acknowledge funding support from the National Institute of Child Health and Human Development (1R21HD072382) and the National Health and Medical Research Council (Program Grant 568612 and Project Grant 1045065). Study sponsors had no role in the research.

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.